HOME PRODUCTS SERVICES COMPANY CONTACT FAQ

Male Breast Neoplasms (Male Breast Cancer)

Subscribe to New Research on Male Breast Neoplasms

Any neoplasms of the male breast. These occur infrequently in males in developed countries, the incidence being about 1% of that in females.

Also Known As:

Male Breast Cancer; Breast Neoplasms, Male; Breast Cancer, Male; Breast Carcinoma, Male; Breast Tumors, Male; Neoplasms, Male Breast; Tumors, Breast, Male; Breast Neoplasm, Male; Breast Tumor, Male; Cancer, Male Breast; Carcinoma, Male Breast; Male Breast Carcinoma; Male Breast Neoplasm; Male Breast Tumor; Male Breast Tumors; Neoplasm, Male Breast; Tumor, Male Breast; Tumors, Male Breast; Neoplasms, Breast, Male

Networked: 315 relevant articles (22 outcomes, 30 trials/studies)

Relationship Network

Disease Context: Research Results

Related Diseases

1.	Breast Neoplasms (Breast Cancer)
2.	Neoplasm Metastasis (Metastasis)
3.	Kidney Neoplasms (Kidney Cancer)
4.	Neoplasms (Cancer)
5.	Gynecomastia

Experts

1.	van Diest, Paul J: 10 articles (12/2015 - 01/2012)
2.	Kornegoor, Robert: 8 articles (11/2013 - 01/2012)
3.	Barba, Maddalena: 6 articles (11/2015 - 08/2013)
4.	Sergi, Domenico: 6 articles (11/2015 - 08/2013)
5.	Pizzuti, Laura: 6 articles (11/2015 - 08/2013)
6.	Vici, Patrizia: 6 articles (11/2015 - 08/2013)
7.	Di Lauro, Luigi: 6 articles (11/2015 - 08/2013)
8.	Maugeri-Saccà, Marcello: 6 articles (11/2015 - 08/2013)
9.	Speirs, Valerie: 5 articles (11/2015 - 01/2011)
10.	De Maria, Ruggero: 5 articles (11/2015 - 09/2014)

Drugs and Biologics

Drugs and Important Biological Agents (IBA) related to Male Breast Neoplasms:

1.	HormonesIBA 12/01/2007 - "The aim of the present study is to analyse the cases of male breast carcinoma as regards its incidence, family history, clinical presentation, staging, histopathological grade, hormone receptor status and to identify the prognostic significance of the above factors on the final outcome. " 06/20/2015 - "Within the Male Breast Cancer Pooling Project, an international consortium comprising 21 case-control and cohort investigations, a subset of seven prospective cohort studies were able to contribute prediagnostic serum or plasma samples for hormone quantitation. " 06/01/2015 - "Male breast cancer shows different biological patterns compared with FBC, with higher positive hormone-receptor status and lower HER-2 overexpression. " 01/01/2014 - "Male breast cancer reacts effectively to endocrine therapy because of a high frequency of hormone receptor expression.The" 01/01/2013 - "Nevertheless, because hormone imbalance has been strongly related to male breast cancer, hormone levels may need to be followed in male patients who have this rare malady. "
2.	Tamoxifen FDA LinkGeneric 04/01/1979 - "This case, added to others reported, suggests that tamoxifen may be useful in the treatment of advanced male breast cancer. " 08/01/2015 - "Twenty-eight Romanian men-17 right-handed and 11 left-handed-undergoing treatment with tamoxifen for male breast cancer participated in this study. " 06/01/2012 - "To our knowledge, this is the largest study examining tamoxifen-related toxic effects among male breast cancer patients. " 08/01/2015 - "A Pilot Study on Tamoxifen Sexual Side Effects and Hand Preference in Male Breast Cancer." 08/01/2015 - "Tamoxifen remains the standard hormonotherapy for Male breast cancer patients (MBC). "
3.	Estrogens (Estrogen)FDA Link 05/28/1977 - "The authors study estrogen (RE) and progestogen (RP) receptors by an exchange technique in 8 cases of male breast carcinoma and 7 cases of gynaecomastia. " 01/01/2016 - "The current literature suggests that genetic factors including BRCA2 mutations, family history, age, androgen/estrogen imbalance, and environmental exposures may predispose to male breast cancer. " 01/01/2014 - "The 21-gene recurrence score assay (Oncotype DX™) in estrogen receptor-positive male breast cancer: experience in an Israeli cohort." 01/01/2010 - "The descriptive analysis showed that the majority of veterans with male breast cancer were non-Hispanic white (60%), older than 65 years at diagnosis (56%), and more likely estrogen receptor positive (45%). " 06/01/2007 - "Three of 4 male breast tumors with BRCA1 mutations (75%) were estrogen receptor positive. "
4.	Aromatase InhibitorsIBA 05/01/2015 - "Aromatase inhibitors in male breast cancer: a pooled analysis." 09/01/2014 - "We searched PubMed from its inception until March 2014 for relevant literature on the use of aromatase inhibitors in metastatic male breast cancer. " 09/01/2014 - "In this manuscript, we discuss relevant aspects of the current use of aromatase inhibitors in metastatic male breast cancer in light of the most updated evidence on the molecular landscape of the disease and the specific changes in the hormonal background occurring with aging. " 09/01/2014 - "Aromatase inhibitors are widely used for treating metastatic male breast cancer patients. " 09/01/2014 - "Aromatase inhibitors for metastatic male breast cancer: molecular, endocrine, and clinical considerations."
5.	Gonadotropin-Releasing Hormone (GnRH)FDA Link 01/01/2015 - "Much controversy exists over the use of gonadotropin-releasing hormone analogues in metastatic male breast cancer patients. " 01/01/2015 - "Role of gonadotropin-releasing hormone analogues in metastatic male breast cancer: results from a pooled analysis." 06/11/2013 - "In this retrospective chart review, cases of male breast cancer patients treated with AIs with or without a GnRH analogue were evaluated. " 06/11/2013 - "Our study shows that AIs with or without GnRH analogues may represent an effective and safe treatment option for hormone-receptor positive, pretreated, metastatic, male breast cancer patients." 11/01/2014 - "We evaluated the activity of cyproterone acetate, either as a monotherapy or combined with a GnRH analog, in 36 metastatic male breast cancer patients. "
6.	Cyproterone AcetateIBA 05/15/1985 - "Cyproterone acetate is an effective and well-tolerated treatment for metastatic male breast cancer." 01/01/1982 - "These results suggest that cyproterone acetate may be useful in the treatment of advanced male breast cancer." 01/01/1982 - "Cyproterone acetate in advanced male breast cancer." 11/01/2014 - "We evaluated the activity of cyproterone acetate, either as a monotherapy or combined with a GnRH analog, in 36 metastatic male breast cancer patients. " 07/15/1993 - "Combined treatment with buserelin and cyproterone acetate in metastatic male breast cancer."
7.	Progesterone Receptors (Progesterone Receptor)IBA 02/01/1998 - "We report, for the first time, a high frequency of LOH at chromosome 13q12-13 in sporadic male breast cancer and its association with factors indicating a poor prognosis for this tumor (e.g., lymph node metastasis and negative progesterone receptor status). " 01/01/2016 - "Our results demonstrated that although adjuvant systemic therapy is used extensively in male breast cancer patients and prognosis has improved over the last few decades, lymph node involvement, and estrogen/progesterone receptor status are still the most important prognostic factors. " 05/01/2000 - "The prognostic role of ploidy status, S phase fraction, estrogen and progesterone receptor status, and the expression of p53 and erbB-2 protein in male breast carcinoma (MBC) remains controversial. " 11/01/1982 - "Cytoplasmic and nuclear estrogen and progesterone receptors in male breast cancer." 08/01/2002 - "The aim of this study is to evaluate the expression patterns of estrogen receptor (ER), progesterone receptor (PR), MiB1 (Ki67), Her-2/neu (c-erbB2), and p53 and to correlate them with the prognosis, presentation, staging, management, and survival/outcome in male breast carcinoma identified through the Veterans Administration nationwide cancer registry. "
8.	Phenobarbital (Luminal)FDA Link 01/01/2014 - "Our study revealed that the luminal A and B subtypes were the major types of male breast carcinoma. " 01/01/2009 - "In our study group, luminal A and B subtypes were the major subtypes of male breast carcinoma. " 01/01/2014 - "The luminal A and B subtypes were the major types of male breast carcinoma (60.9%, 34.8% respectively). " 01/01/2009 - "The luminal A subtype was the most common subtype in male breast cancer (83%, 35/42), which was followed by the luminal B subtype (17%, 7/42). " 06/01/2012 - "Notably, AR-positive luminal A male breast cancer had improved overall survival over female breast cancer at 5 (P = 0.01, HR = 0.39, 95% CI = 0.26-0.87) but not 10 years (P = 0.29, HR = 0.75, 95% CI = 0.46-1.26) and both 5 (P = 0.04, HR = 0.37, 95% CI = 0.07-0.97) and 10 years (P = 0.04, HR = 0.43, 95% CI = 0.12-0.97) in the unselected group. "
9.	fulvestrant (Faslodex)FDA Link 01/01/2015 - "All studies that examined the efficacy of fulvestrant in male breast cancer, regardless of sample size, were considered eligible. " 01/01/2015 - "However, further clinical and pharmacokinetic investigations are more than warranted before fulvestrant use becomes a common practice in male breast cancer patients." 01/01/2015 - "This is the first pooled analysis of the literature to synthesize all available data and to evaluate the efficacy and safety of fulvestrant in male breast cancer. " 01/01/2015 - "Fulvestrant and male breast cancer: a pooled analysis." 01/01/2013 - "Fulvestrant and male breast cancer: a case series."
10.	letrozole (Femara)FDA LinkGeneric 04/01/2005 - "Successful use of letrozole in male breast cancer: a case report and review of hormonal therapy for male breast cancer." 08/01/2013 - "In this retrospective study we evaluated the activity of letrozole combined with a gonadotropin-releasing hormone analog as a first- or second-line therapy for metastatic male breast cancer patients. " 08/01/2013 - "Letrozole combined with gonadotropin-releasing hormone analog for metastatic male breast cancer." 08/01/2013 - "The combination of letrozole and gonadotropin-releasing hormone analog is effective and safe in hormone-receptor positive, metastatic male breast cancer patients." 01/01/2011 - "Although the aromatase inhibitors such as anastrozole, exemestane, and letrozole are very active in postmenopausal women with hormone receptor positive breast cancer, their efficacy in male breast cancer has not been demonstrated in phase II or III trials. "

Therapies and Procedures

1.	Mastectomy (Mammectomy) 11/01/2002 - "Previous studies of male breast cancer have suggested that due to the lack of breast tissue, post-mastectomy radiation should be routinely utilized in all stages of this disease. " 02/01/2012 - "The impact of post-mastectomy radiation therapy on male breast cancer patients--a case series." 06/01/2011 - "Among the five cases of male breast cancer who received surgery at our hospital, mastectomy with SLNB was performed in two of the cases. " 12/01/2009 - "Male breast cancer patients almost always underwent mastectomy and a significant proportion of them (11%) received no surgical treatment. " 01/01/2009 - "Furthermore, genetic testing and risk-reducing mastectomy should also be considered in cases of a strong family history for male breast cancer."
2.	Drug Therapy (Chemotherapy) 01/01/2015 - "Efficacy of chemotherapy in metastatic male breast cancer patients: a retrospective study." 01/01/2015 - "Chemotherapy, consisting in both anthracycline-containing and anthracycline-free regimens, showed encouraging antitumor activity in metastatic male breast cancer patients previously treated with endocrine therapy." 01/01/2015 - "The role of chemotherapy in the treatment of metastatic male breast cancer patients remains unknown, and the only available evidence stem from small, retrospective series evaluating outdated drugs and/or regimens. " 06/01/2002 - "Pharmacotherapy for male breast cancer." 02/01/1995 - "Treatment of locally recurrent male breast cancer by regional chemotherapy."
3.	Modified Radical Mastectomy (Mastectomy, Modified) 01/01/2015 - "Modified radical mastectomy has been favored in all female SBC, male SBC and usual type of male breast cancer. " 12/01/2007 - "Male breast cancer in general is treated by modified radical mastectomy. " 01/01/2005 - "Modified radical mastectomy followed by external radiation therapy is the standard treatment for male breast cancer. " 05/01/1993 - "We conclude that radical or modified radical mastectomy is the rational therapy for male breast cancer. " 12/01/2010 - "The changes in therapeutic strategies were determined and the efficacy of radical mastectomy (RM) and modified radical mastectomy (MRM) on Chinese male breast cancer (MBC) patients was compared. "
4.	Segmental Mastectomy (Lumpectomy) 05/01/2013 - "Outcomes of partial mastectomy in male breast cancer patients: analysis of SEER, 1983-2009." 01/01/2008 - "Breast conserving surgery with preservation of the nipple-areola complex as a feasible and safe approach in male breast cancer: a case report." 12/01/2007 - "Breast-conserving surgery in male breast cancer patients should be considered an option in patients without overt nipple/areolar involvement." 05/01/2013 - "Although mastectomy is considered the gold standard for male breast cancer (MBC), the utilization of lumpectomy and its impact on outcomes in MBC patients has not been previously studied. " 03/01/2004 - "Breast conserving surgery, performed in selected cases of male breast cancer, should be always followed by radiotherapy. "
5.	Radical Mastectomy 08/01/2008 - "For male breast cancer, radical mastectomy is no longer a common treatment modality. " 12/01/2010 - "The changes in therapeutic strategies were determined and the efficacy of radical mastectomy (RM) and modified radical mastectomy (MRM) on Chinese male breast cancer (MBC) patients was compared. " 07/01/2002 - "A rare case of advanced male breast cancer in a patient on hemodialysis was successfully treated with radical mastectomy and chemotherapy. "